Cellectar Enrolls First DLBCL Patient in Phase 2 Trial Testing CLR 131 in Refractory B-cell Cancers
News
Cellectar Biosciences has recruited the first patient with diffuse large B-cell lymphoma (DLBCL) into its Phase 2 clinical trial testing the company’s lead investigational phospholipid-drug conjugate, CLR 131. The trial includes ... Read more